Table 2.
Risk of lung cancer in relation to MDM2 SNP309 and p53 codon 72 polymorphisms
| Genotype | Cases (n = 123) | Controls (n = 159) | Age- and birthplace-adjusted1odds ratio (95% CI) | |
|---|---|---|---|---|
| No. (%) | No. (%) | |||
| MDM2 SNP309 | ||||
| GG | 29 (23.6) | 51 (32.1) | 1.00 | |
| TG | 65 (52.8) | 83 (52.2) | 1.42 (0.80-2.52) | |
| TT | 29 (23.6) | 25 (15.7) | 2.10 (1.01-4.36) | |
| P53 codon 72 | ||||
| Arg/Arg | 28 (22.8) | 42 (26.1) | 1.00 | |
| Arg/Pro | 69 (56.1) | 88 (54.7) | 1.21 (0.67-2.17) | |
| Pro/Pro | 26 (21.1) | 31 (19.3) | 1.44 (0.70-3.00) | |
| Combined genotype2 | ||||
| P53 codon 72 | MDM2 SNP309 | |||
| Arg/Arg | GG/TG | 24 (85.7%) | 32 (76.2%) | 1.00 |
| TT | 4 (14.3%) | 10 (23.8%) | 0.58 (0.15-2.22) | |
| ArgPro/ProPro | GG/TG | 69 (73.4%) | 102 (87.2%) | 1.00 |
| TT | 25 (26.6%) | 15 (12.8%) | 2.42 (1.16-5.03) | |
1 Adjusted for age in years and birthplace (China-born, Singapore/Malaysia-born). All individuals were lifetime non-smoker Chinese women.
2 P (interaction) = 0.06